Cargando…

The unexpected finding of a hemangioblastoma on the cerebellum of a patient undergoing treatment with natalizumab for multiple sclerosis

Detalles Bibliográficos
Autores principales:	Fragoso, Yara Dadalti, Brooks, Joseph Bruno Bidin, Reghin Neto, Mateus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Tehran University of Medical Sciences 2017
Materias:	Letter to Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5526784/ https://www.ncbi.nlm.nih.gov/pubmed/28761632

Ejemplares similares

Early and severe cognitive impairment in multiple sclerosis
por: Mendes, Maria Fernanda, et al.
Publicado: (2012)

Interferons and Natalizumab for Multiple Sclerosis
por: Clar, Christine, et al.
Publicado: (2008)

Natalizumab in the treatment of multiple sclerosis
por: Brown, Brandon A
Publicado: (2009)

The use of natalizumab for multiple sclerosis
por: Brandstadter, Rachel, et al.
Publicado: (2017)

Natalizumab Rebound in Multiple Sclerosis
por: Lee, Joshua D., et al.
Publicado: (2021)

Adherence to glatiramer acetate treatment for multiple sclerosis: the Brazilian experience
por: de Oliveira, Tatiana de Melo Gomes, et al.
Publicado: (2008)

Practical Evidence-Based Recommendations for Patients with Multiple Sclerosis Who Want to Have Children
por: Fragoso, Yara Dadalti, et al.
Publicado: (2018)

Natalizumab for the treatment of relapsing multiple sclerosis
por: Rudick, Richard A, et al.
Publicado: (2008)

Effect of 12 weeks of aquatic strength training on individuals with multiple sclerosis
por: SCORCINE, Claudio, et al.
Publicado: (2022)

Natalizumab in Multiple Sclerosis: Long-Term Management
por: Clerico, Marinella, et al.
Publicado: (2017)

Glioblastoma in natalizumab‐treated multiple sclerosis patients
por: Sierra Morales, Fabian, et al.
Publicado: (2017)

Hemangioblastoma masquerading as a ring enhancing lesion in the cerebellum: A case report
por: Li, Li, et al.
Publicado: (2022)

Systematic review of the published data on the worldwide prevalence of John Cunningham virus in patients with multiple sclerosis and neuromyelitis optica
por: Paz, Sonia Patricia Castedo, et al.
Publicado: (2018)

Risk Acceptance in Multiple Sclerosis Patients on Natalizumab Treatment
por: Tur, Carmen, et al.
Publicado: (2013)

The discovery of natalizumab, a potent therapeutic for multiple sclerosis
por: Steinman, Lawrence
Publicado: (2012)

Comparative efficacy of switching to natalizumab in active multiple sclerosis
por: Spelman, Timothy, et al.
Publicado: (2015)

The role of natalizumab in the treatment of multiple sclerosis: benefits and risks
por: Singer, Barry A.
Publicado: (2017)

Cognitive evolution in natalizumab-treated multiple sclerosis patients
por: Jacques, Francois H, et al.
Publicado: (2016)

Relapse-independent multiple sclerosis progression under natalizumab
por: Graf, Jonas, et al.
Publicado: (2021)

Natalizumab in cerebrospinal fluid and breastmilk of patients with multiple sclerosis
por: Callegari, Ilaria, et al.
Publicado: (2023)

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
por: Prosperini, Luca, et al.
Publicado: (2016)

High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients
por: Dwyer, Christopher M., et al.
Publicado: (2021)

The Neurocognitive Profile of the Cerebellum in Multiple Sclerosis
por: Sarica, Alessia, et al.
Publicado: (2015)

Natalizumab: A new treatment for relapsing remitting multiple sclerosis
por: Hutchinson, Michael
Publicado: (2007)

Clinical efficacy issues in the treatment of multiple sclerosis: update of natalizumab
por: Patti, Francesco, et al.
Publicado: (2009)

Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy
por: Gattringer, Thomas, et al.
Publicado: (2014)

Effect of Natalizumab on Circulating CD4(+) T-Cells in Multiple Sclerosis
por: Börnsen, Lars, et al.
Publicado: (2012)

Efficacy and Side Effects of Natalizumab Therapy in Patients with Multiple Sclerosis
por: Hoepner, Robert, et al.
Publicado: (2014)

Disrupted balance of T cells under natalizumab treatment in multiple sclerosis
por: Kimura, Kimitoshi, et al.
Publicado: (2016)

Natalizumab versus fingolimod and dimethyl fumarate in multiple sclerosis treatment
por: Vollmer, Brandi L., et al.
Publicado: (2018)

Natalizumab is Effective for the Treatment of Relapsing-remitting Tumefactive Multiple Sclerosis
por: Nakamura, Masataka, et al.
Publicado: (2017)

Clinical Immunological Correlations in Patients with Multiple Sclerosis Treated with Natalizumab
por: Maier, Smaranda, et al.
Publicado: (2020)

Real-World Effectiveness of Natalizumab in Korean Patients With Multiple Sclerosis
por: Kim, Ki Hoon, et al.
Publicado: (2021)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Natalizumab Pharmacokinetics and -Dynamics and Serum Neurofilament in Patients With Multiple Sclerosis
por: Proschmann, Undine, et al.
Publicado: (2021)

Natalizumab Induces Changes of Cerebrospinal Fluid Measures in Multiple Sclerosis
por: Ganapathy Subramanian, Ranjani, et al.
Publicado: (2021)

Natalizumab Promotes Activation of Peripheral Monocytes in Patients With Multiple Sclerosis
por: Frisch, Esther S., et al.
Publicado: (2023)

Influence of natalizumab on resting-state connectivity in patients with multiple sclerosis
por: Corrêa, Diogo G., et al.
Publicado: (2023)

Reactivation of Human Herpesvirus-6 in Natalizumab Treated Multiple Sclerosis Patients
por: Yao, Karen, et al.
Publicado: (2008)

A meta-analysis on the efficacy and tolerability of natalizumab in relapsing multiple sclerosis
por: Nikfar, Shekoufeh, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_54nf9lt261b650079apjh89rce